Microcosting and Budget Impact Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi

医学 异环磷酰胺 弥漫性大B细胞淋巴瘤 长春新碱 切碎 强的松 肿瘤科 内科学 淋巴瘤 化疗 依托泊苷 环磷酰胺
作者
Matthew Painschab,Racquel E. Kohler,Satish Gopal
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 3558-3558
标识
DOI:10.1182/blood-2018-99-115237
摘要

Abstract INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the commonest NHL subtype in sub-Saharan Africa (SSA), as in other parts of the world. Limited prospective data from the region have shown that DLBCL is curable in a substantial proportion of cases with chemotherapy and appropriate supportive care. However, little is known about costs of DLBCL treatment in the region. METHODS: We conducted a microcosting and budget impact analysis from a health systems prospective in Malawi, a low-income country in SSA. All costs were determined based on real-world costs for treating DBLCL patients at Kamuzu Central Hospital (KCH), a national teaching hospital in Lilongwe, Malawi, as part of a prospective, ongoing, longitudinal cohort study, the KCH Lymphoma Study. We calculated costs of care for palliative care only, first-line chemotherapy with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP), and second-line chemotherapy for relapsed/refractory DLBCL with either ifosfamide, cisplatin, prednisone, and etoposide (EPIC) or gemcitabine and oxaliplatin (GemOx). Cost data were taken directly from costs paid for goods and services at KCH. Costs were calculated on a per-patient, activity basis, and total costs were estimated based on the average patient experience in our cohort through two years of care. Likewise, data from the KCH Lymphoma Study was used to estimate supportive care events and costs, including the number of hospitalizations during treatment for each type of chemotherapy delivered. Personnel costs were calculated based on interviews of clinic personnel, as well as actively observing time spent on clinical activities. Overhead costs consisted primarily of pathology and laboratory infrastructure and were amortized over 25 years. All costs were collected in, or converted to, 2017 USD using Malawian GDP deflator. Total cost is also shown in International Dollars to facilitate comparisons across countries. Finally, using national cancer registry data and data from the KCH Lymphoma Study, we calculated the annual budget impact for Malawi to treat all DLBCL cases. RESULTS: All costs are shown on a per-patient basis (Table 1) using median chemotherapy cycles as received by the historical cohort of patients in the KCH Lymphoma Study, with follow-up visits for two years from chemotherapy initiation. Median number of chemotherapy cycles were as follows: CHOP (5), EPIC (3.5), and GemOx (5). CONCLUSIONS: To our knowledge, this is one of the first studies to rigorously examine cost and budget implications of DLBCL care in SSA. We calculated that first-line chemotherapy with CHOP can be delivered for $1050 more per patient compared with palliative care alone in this single-institution microcosting analysis. Strengths include microcosting based on real-life costs derived from utilization data in this highly resource-limited setting. Although this single-institution study may limit generalizability, these data can help guide resource allocation for a common curable cancer throughout SSA. Planned analyses include an ongoing formal cost-effectiveness analysis to compare DLBCL treatment to other accepted health care interventions in SSA. Disclosures No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI6.3的应助被孤星采纳,获得10
2秒前
luo运俊完成签到,获得积分10
2秒前
科研通AI6.2的应助被yuyu采纳,获得10
2秒前
2秒前
奈何完成签到 ,获得积分10
3秒前
不吃辣完成签到,获得积分10
4秒前
5秒前
5秒前
爱岗敬业牛马人完成签到,获得积分10
5秒前
林慧宁发布了新的文献求助10
5秒前
zzz完成签到,获得积分10
6秒前
7秒前
Menand发布了新的文献求助10
9秒前
隐形曼青的应助被花样年华采纳,获得10
9秒前
xhjiang完成签到,获得积分10
9秒前
刺五加发布了新的文献求助10
10秒前
CaliU发布了新的文献求助10
12秒前
12秒前
努力发AM完成签到,获得积分10
13秒前
清心发布了新的文献求助10
15秒前
16秒前
16秒前
16秒前
乌龙茶完成签到 ,获得积分10
16秒前
16秒前
CJX发布了新的文献求助10
17秒前
车辆学长完成签到 ,获得积分10
17秒前
花样年华发布了新的文献求助10
21秒前
盟主完成签到 ,获得积分10
22秒前
沉静蓉发布了新的文献求助10
22秒前
超表面发布了新的文献求助10
22秒前
annie完成签到 ,获得积分10
24秒前
碧蓝老黑完成签到,获得积分10
24秒前
李健的应助被wm采纳,获得10
24秒前
26秒前
26秒前
26秒前
27秒前
思念变成王年年完成签到,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712